Background: Bovine respiratory disease (BRD) is a worldwide animal health concern especially in feedlot, dairy, and veal calves. One of the greatest challenges is the absence of a gold standard for achieving an accurate antemortem diagnosis. Various blood markers, including the acute-phase proteins (AAP), have been proposed as potential valuable tools for BRD diagnosis.
D
espite advances in veterinary medicine, animal husbandry, and animal welfare, bovine respiratory disease (BRD) continues to be the most economically significant disease in feedlots 1, 2 and one of the most important causes of morbidity and mortality in dairy calves 3 and veal calves. 4 Relapses, mortality, propagation of infectious agents, and retarded growth or impaired production performance can be observed as consequences of BRD in addition to the associated costs for processing sick calves (monitoring and treatments). [5] [6] [7] Effective control of BRD has proven to be difficult in the North American dairy and beef industries, at least in part due to the complexity of disease pathogenesis and the ubiquity of BRD-associated pathogens. 2 One of the greatest challenges for feedlot personnel or dairy farmers is an early and accurate diagnosis of BRD. In previous studies, [8] [9] [10] it has been reported that 37-68% of steers that never receive a diagnosis of BRD during the finishing period have lung lesions at slaughter. Pen-rider accuracy has been reported to be only moderate with a sensitivity (Se: proportion of accurately diagnosed BRD cases) of 61.8% and specificity (Sp: proportion of accurately diagnosed non-BRD cases) of 62.8% as determined using a latent class analysis with no gold standard. 11 In dairy herds, clinical diagnosis also lacks accuracy, 12, 13 and the same is true in veal calves where clinical signs, such as abnormal breathing, nasal discharge, and cough, were not accurate to predict moderate to severe lung lesions at slaughter. 4 To improve diagnostic accuracy, several authors have focused on ancillary tests using various blood biomarkers. [14] [15] [16] Among the potential biomarkers, the acute-phase proteins (APP) change in concentration after infection, inflammation, surgical trauma, or stress 17 and can either increase (positive APP) or decrease (negative APP) as a consequence of inflammatory stimuli. Haptoglobin (Hp), serum amyloid A (SAA), and fibrinogen (Fb) are among the most commonly reported APP. 18 The C-reactive protein (CRP) has also been mentioned in various species (eg, human or dog) as an important APP but has received limited interest in cattle. 18 The serum increase of APP can occur as soon as 4 hours after the insult for SAA or CRP or later (24-48 hours) for Hp or Fb. 18 The diagnostic and prognostic potential of measuring APP in cattle with BRD has been suggested a but is variably supported by the literature. As an example, Hp has been considered useful for identifying beef calves with BRD needing treatment and for monitoring treatment efficacy. 14, 19 In contrast, other studies found that Hp had limited capacity as a diagnostic clinical tool for BRD in feedlot cattle. 8, 20 Such discrepancy might indicate: (1) that not all pathogens involved in BRD increase serum Hp concentrations to the same extent, which might mitigate its accuracy in naturally occurring BRD (where the exact etiology is rarely known); (2) differences might occur due to sampling heterogeneity; or (3) differences might result from variability in study design and case definition. Diagnostic test accuracy refers to the ability of a test to distinguish between patients with disease (Se) and those without disease (Sp). 21 As for therapeutic and preventive measures, evidence-based veterinary medicine using systematic reviews can be used for assessing published literature on test accuracy to assess the strengths and weaknesses of the evidence available. 22 To date, the systematic assessment of diagnostic test accuracy has been uncommonly used in veterinary medicine and animal science. 23, 24 The aim of this study was, therefore, to perform a systematic review/meta-analysis concerning selected APP (Hp, SAA, and Fb) as diagnostic tools for cattle with naturally occurring BRD when compared with the reference standard used to diagnose BRD in each study.
Materials and Methods

Search Strategy
The literature search strategy used was based on the recommendations for Systematic Reviews of Diagnostic Test Accuracy from the Cochrane Diagnostic Test Accuracy Working Group. 21 Relevant publications were identified through an initial search of Ovid (CAB Abstract and MEDLINE) from 1946 to February 2015. We used, with the help of a librarian, a combination of controlled vocabulary keywords and Medical Subject Headings (MeSH) focusing on BRD and APP (Appendix S1). A "gray" literature search was also performed through Google Scholar to identify research abstracts from meeting proceedings or unpublished studies. Furthermore, the reference lists of review articles were consulted to look for any references not included in the systematic review list. The titles and abstracts of all studies identified in the initial literature search were subsequently screened for eligibility by 2 authors (AA and SB).
Eligibility Criteria
In the first round of screening, titles and abstracts were screened for inclusion based on potential relevance. Experimental BRD research articles, articles presenting case series (ie, only BRDpos cases), review articles, nonrelevant articles (ie, not reporting cattle respiratory disease and topics not related with the study objective), and articles not published in English were excluded. Prognostic studies were also excluded from this systematic review. A prognostic study was a study where the APP was measured and the BRD status was determined prospectively (time to event approach, in general >24 hours after APP measurement). Since the delay between the index test (APP) and the reference standard (BRDpos or BRDneg case assessment) not standardized at a fixed time (time to event studies with censored data), those studies were excluded. By extension, we excluded studies where the reference standard and the index test were performed with >1 day between them. Following preliminary screening, full-text copies of potentially relevant articles were obtained and further reviewed. Eligibility criteria for inclusion were independently assessed by 2 reviewers (AA and SB) using the same strategy as performed at the title and abstract level. A consensus between both reviewers was required to exclude an article at this stage of screening.
Data Extraction
Study information and available raw data were extracted from all the selected studies by the same person (AA) and compiled in a spreadsheet.
b A second author (SB) independently extracted the same information and then a face-to-face meeting was done to double check the data. Study characteristics that were systematically recorded included APP studied, the type of patient (dairy or beef), age range (defined as calves if <1 year, adults if ≥1 year), and criteria used for defining the clinical reference standard (ie, definitions of BRDpos and BRDneg cases in the study) to be used as the gold standard against which to assess the APP accuracy. Since study design can impact assessment of diagnostic test accuracy, 25 the design of each study was recorded as a 1-gate design (if BRDpos and BRDneg cases were selected from the same population following the same diagnostic testing in both groups) or as a 2-gate design (if BRDpos and BRDneg cases were diagnosed using different inclusion criteria, eg, the BRDneg definition was based on healthy animals that received no diagnostic testing or cases with a disease other than BRD that received alternate testing). Since disease prevalence 26 can also impact the Se/Sp of a diagnostic test, the BRD prevalence (P BRD ) of each study was also recorded using the formula:
The tests used for APP quantification, the cutoff used to define BRDpos, and the method used to determine this cutoff (ie, whether it was predetermined based on previously published studies or was data driven) were noted if present, as well as details of the 2 by 2 tables [true-positive (TP), false-positive (FP), falsenegative (FN), and true-negative (TN) cases]. In situations where either the cutoff or the 2 by 2 table were available in the report, the authors were contacted 3 times if an e-mail address was listed, in order to get the raw data or unpublished 2 by 2 tables. When raw data were obtained, the cutoff used was the cutoff that minimized misclassification by the APP (ie, provided the maximal Se + Sp value).
Methodological Quality Assessment
A quality assessment of every retained article was performed using the Quality Assessment of Diagnostic Test Accuracy 2 (QUADAS-2) tool. 27 The QUADAS-2 process categorizes the risk of potential bias and study applicability when evaluating diagnostic tests, generating ratings of low, unclear or high risk of bias (Table 1 ). This tool assesses internal and external validity of studies based on the design, the diagnostic (index) test used, and the definitions of positive and negative cases. The QUADAS-2 tool consists of 4 key domains to assess the risk of bias, including patient selection, the index test used (ie, the APP), the reference standard (the test considered as the gold standard [in our case the definition of BRDpos and BRDneg] against which index test results are compared), and flow and timing of patients and index test application in the study. The risk of bias for the timing was assessed as low if it was explicitly stated that the APP and BRD status were determined at the same moment. It was classified as unclear when no explicit statement indicated the exact delay, but there was no indication that this delay could not exceed 1 day. The risk of bias for study flow was assessed taking into account whether all the patients received a reference standard and if it was the same reference standard (eg, not a different test to define BRDpos versus BRDneg cases) as well as if all the patients were included in the analysis. When the information was not present, Is there concern that the included patients do not match the review question?
The patients are first-line cases with no selection of more advanced BRD stages
The patients are chronic cases with obvious BRD signs
Is there concern that the index test, its conduct, or interpretation differ from the review question?
The test is a commercially validated test that can be used in future studies
The test is developed for that particular study without further details
Domain 3: reference standard
Is there concern that the target condition as defined by the reference standard does not match the review question?
The BRD status is determined by the use of multiple tests results (combination of physical examination, temperature, and ancillary tests)
BRD-positive cases defined as anorectic and pyretic animals with no further testing a A study was excluded if BRD status was assigned >1 day after the APP sampling date.
an unclear risk was assigned. Furthermore, applicability of each retained article to the systematic review question was also assessed by the QUADAS-2 tool through 3 items that consider patient selection, the index test itself, and the reference standard test used. Both reviewers (AA and SB) scored each study independently using this 7-item tool. Any disagreements were resolved to consensus during a face-to-face discussion about each disagreement. When continued disagreement was present, a third reviewer was solicited (JH or DF) and the final decision was based on that review and final consensus.
Statistical Analysis
Descriptive statistics were used for the study characteristics. Paired forest plots of sensitivity and specificity were obtained based on 2 by 2 table results using specific freeware for systematic review.
c The information gathered included the true-positive cases (TP: cases ≥ APP cutoff and BRDpos); false-positive cases (FP: cases ≥ APP cutoff and BRDneg); false-negative cases (FN: cases < APP cutoff and BRDpos), and true-negative cases (TN: cases < APP cutoff and BRDneg). Moses-Littenberg summary receiver-operating characteristic (sROC) curves were used by default in RevMan for a visual description of the accuracy obtained for the multiple tests in the different studies. The SROC curve is a good visual graph that helps for preliminary data analysis before exploring more complex models. This curve is obtained based on the true-positive fraction (TPF = Se = TP/(TP + FN)) and the false-positive fraction (FPF = (1-Sp) = FP/(FP + TN) of every study based on fitting the linear mixed model:
where a and b are the intercept and regression coefficient estimated from the studies' results and e i is the random error in the study i D ¼ logitðTPFÞ À logitðFPFÞ; ð3Þ
As the number of studies in which Se/Sp could be obtained was low, with heterogeneity in BRDpos and BRDneg definitions as well as test cutoffs chosen, it was not appropriate to calculate pooled estimates of these values. 28 For these reasons, no further statistical analysis models were attempted.
Results
Our initial search strategy retrieved 385 articles from CAB Abstracts and MEDLINE and 34 articles from Google Scholar. The flow diagram outlining the selection strategy to obtain 25 articles is summarized in Figure 1 . Twenty-three studies, 29-49,d ,e were ultimately included. Two articles described studies already reported in different journals. 46, 47 Study Characteristics and BRD Definitions Table 2 shows the characteristics of the 23 studies that were retained for analysis. Eighteen studies used calves, while 5 studies enrolled adult cattle as target animals. Seventeen studies (74%) used a 2-gate design, where healthy animals (n = 12) and animals with another diagnosis than BRD (n = 5) were included as controls. Only 6 studies (26%) used a 1-gate design. Four of 23 (17%) studies estimated all selected APP (Hp, SAA, and Fb) for BRD diagnosis; 8 (35%) studies assessed both Hp and SAA, 2 (9%) studies assessed both Hp and Fb, 5 (22%) studies estimated Hp, and 4 (17%) studies evaluated Fb as a single diagnostic marker.
The BRDpos and BRDneg case definitions used in the different studies are summarized in Table 3 . Sixteen (70%) studies used clinical examination only as the reference standard for diagnosing BRD, whereas 6 (26%) studies applied a combination of clinical and laboratory methods as their reference standard for BRD diagnosis (2 of them also included APP results in the case definition). The remaining study 46 used clinical examination in addition to ultrasonography and endoscopic examination in some cases to diagnose BRD. Two studies Flow diagram for the study selection process. Gray literature searched through Google Scholar. *A predictive study was a study where the acute-phase protein (APP) was measured and the status relative to bovine respiratory disease (BRD) was determined prospectively. Since the delay between the index test (APP) and the reference standard (BRDpos or BRDneg case assessment) was delayed and not standardized at a fixed time (time to event studies with censored data), those studies were excluded. **n = 4 others: Analytical papers (n = 2), BRD status based on serologic status (n = 1), and study assessing pathogenic factors of pneumonic pasteurellosis (n = 1). used transtracheal and bronchoalveolar fluid culture to determine the causative agent of BRD. 31, 33 Only 5 (22%) of the 23 studies clearly reported their criteria for definition of BRDneg cases.
Quality Assessment
Overall, quality assessment was rated as a high or unclear risk of bias or applicability, with only index test applicability being rated as low for risk of bias (Fig 2) . The risk of bias in patient selection was considered high in 17 (74%) studies, mainly because of the 2-gate (casecontrol) design used in the majority of studies. The risk of bias in performance of the index test was considered unclear in 15 (65%) studies. The risk of bias for reference standard definition was unclear in the majority of studies (n = 17; 74%). The risk of bias arising from patient flow and timing of procedures was considered unclear in the majority of studies, mostly because in almost all studies it was not clear if a reference standard was performed in every patient (or whether that standard could have been performed differently in the BRDneg and BRDpos cases), if all cases were included for analysis, or if the interval between index test and reference standard determination was appropriate or not. Regarding applicability, there was high risk identified for patient selection and the reference standard, but a low risk for index test application since most studies reported commercially validated tests used under controlled conditions.
Index Test (APP) Application
The different techniques used for APP quantification are illustrated in Table 4 . Cutoffs and data relative to the 2 by 2 tables were available in 8 studies (35%) involving Hp, 5 studies (22%) with SAA, and 4 studies (17%) with Fb. Results also showed that in 15 (65%) studies, it was unclear if the cutoff point was prespecified or not. We obtained the cutoff points and the 2 by 2 tables from 6 out of the 17 contacted authors (35%).
Accuracy Measurements
The accuracy of the different APP is summarized in Figures 3 and 4 . The sROC was indicative of higher accuracy for Hp due to its closer fit to the upper left corner of the ROC space. For Hp, the Se varied from The most commonly reported 2-gate design was using clinically healthy animals as the controls. In the case of an alternative diagnosis, the nondiseased animals were animals that had a disease different from BRD. 
Discussion
We reviewed the literature to determine the diagnostic accuracy of haptoglobin, serum amyloid A, and fibrinogen, as relevant acute-phase proteins in naturally occurring BRD using an evidence-based approach. When performing a systematic review, it is essential that a very defined research question is posed and that inclusion and exclusion criteria are determined a priori to directly investigate that question. In our systematic review on the sensitivity and specificity of acute-phase protein determination to diagnose BRD, our research question was confined to use of these tests in the clinical setting. This restricted our final database to only those studies involving naturally occurring BRD, which we felt would more likely yield a better representation of APP test performance under realistic conditions of test use. Test assessment during experimentally induced disease or when applied to use on only severely affected animals (ie, case series reports) would have shown inflated Se and Sp outcomes, and so these studies were intentionally excluded during our systematic review of the literature. Fig. 2 . Summary of the methodological quality of included studies on the basis of authors' assessments regarding the 4 domains assessing the risk of bias and the 3 domains assessing applicability concerns of the Quality of Diagnostic Accuracy Study-2 checklist for each study. In green are highlighted the number of studies with a low risk of bias or low applicability concern and in red the studies with a high risk of bias or high applicability concerns. The number of studies in yellow indicates the studies where these risks of bias or applicability concerns could not be assessed properly (unclear). For this specific study, the BRD prevalence was calculated using the animals where APP was measured (Fig 3) , versus 41% from calculated directly from the original study.
We have found that there are a relatively low number of studies where accuracy of the APP was presented in terms of Se and Sp. By including only studies of APP assessment under field conditions, we were able to identify only 23 studies over the period of 1946-2015 that met our inclusion criteria. These 23 studies reported variable Se and Sp of each APP in diagnosing BRD, with generally improved test performance for Hp over fibrinogen and SAA in cattle with BRD although not statistically different. These 23 reports included a variable mix of which APP were studied; therefore, the actual number of studies for each APP (Fb, SAA, and Hp) upon which our systematic review conclusions could be based was even fewer. In our systematic review, we sought to determine the collective Se and Sp of each APP for diagnosing BRD based on the existing literature. However, there were a relatively small number of studies where 2 by 2 tables or data were available to assess diagnostic test accuracy, even after contacting 17 of the authors with 3 reminders. This emphasizes the need for future reporting of data in such a way as to allow calculation of Se/Sp estimates as well as BRD prevalences. The use of different cutoffs between studies was also a limitation to obtain pooled estimates of Se and Sp using a bivariate analysis. 58 In this situation, the determination of a hierarchical summary ROC (HSROC) model can be used, assuming that a cutoff effect exists (ie, when the Se increases, the Sp decreases). 59 However, because of the relatively small number of studies and the highly variable definitions of BRDpos and BRDneg cases and studies particular settings, we could not determine these accuracy parameters. Due to this, our ability to make firm conclusions or to perform meta-analysis of the data was impaired. Another limitation of true APP accuracy determination is that APP response can also be caused by various stressors, which could potentially affect its specificity for BRD detection. As an example, castration might occur for feedlot calves with a short delay before being on feed and is also associated with increased Hp concentrations. 60 Haptoglobin concentration can also increase after stressful experimental events such as transportations for 2-day 61 or 3-day starvation. 62 All these situations could potentially have a negative impact on APP specificity.
During the systematic review process, it is also important to assess the scientific merits of the papers ultimately selected for inclusion, in order to make judgment on the strength of the conclusions that are drawn from the systematic review analysis. In our study, we employed the QUADAS-2 system for assessing applicability of the studies to our research question and for assessment of any risks of bias in our included studies, in order to better understand whether our conclusions were appropriate and to identify any limitations to our review. Applicability of each study was evaluated in terms of relevance of the index test, reference standard, and population used to our research question. Areas of potential bias that were assessed and included the following: method of case classification (the reference standard used to diagnose BRD in each study), how the index test (APP measurement) was employed during the diagnostic process, methods of patient selection, and timing of measuring the APP. In general, the majority of studies had high applicability to our research question in that the index test was used in our population of interest in a manner similar to the intended clinical application during field diagnosis of naturally occurring BRD in cattle. However, in terms of potential bias of the included studies as assessed by the QUADAS2 tool, high risk of bias was identified regarding allocation of cattle into BRDpos and BRDneg groups. The BRD case definition (ie, the reference standard) was variable between studies, which is a common feature across all types of BRD studies and arises from the absence of a consensus concerning how to diagnose BRD in dairy or beef cattle.
f The BRDpos definition was mainly clinically derived and based on various combinations of clinical signs, including fever, depression, nasal discharge, cough, increased respiratory rate, and abnormal lung sounds on auscultation (crackles, wheezes, and harsh sounds). Of these signs, using differing combinations of signs had the potential to significantly impact BRD classification. Using differing combinations of clinically derived signs in populations of differing true BRD prevalence would result in underestimating the number of BRD cases in situations of high disease prevalence and imperfect sensitivity, and more likely, in populations of low disease prevalence and imperfect specificity, to overestimate the number of BRD cases. The use of an established clinical scoring system can improve disease detection to some degree. 5, 63 If misclassification by the reference standard is not estimated, this would bias the accuracy estimates of the index tests (APPs measured) in each study. Similarly, the exact BRDneg definition was infrequently defined, which could also be perceived as a limitation on the interpretation of apparent test specificity; in general, the use of healthy animals to represent the BRDneg comparison group would lead to overestimating the index test specificity. 25 The differential reference bias, in which the reference standard is not applied in the same manner between BRDpos and BRDneg cases, can also have an impact on Se/Sp. 64 Only 5 studies clearly defined how BRDneg cases were determined. When applying the same reference standard to classify the cases, one could guess that this definition is the complement of the BRDpos definition. However, if not specifically stated, it is difficult for the reader to be sure of that precise definition which often resulted in us having to assign an "unclear" risk of bias in many studies for the reference standard.
The use of APPs (index test) as a part of the reference standard tests (known as incorporation bias) was only observed in 2 studies where case definition was based on both the presence of clinical signs and Hp values above a specified cutoff. Using this definition could obviously overestimate the Se of APP.
Using the QUADAS2 tool, we detected "high" or "unclear" risk of bias on the Se and Sp of the various acute-phase proteins, resulting from how patients were identified or enrolled. Of the various methodological weaknesses that could make diagnostic studies vulnerable to bias, the use of 2 gate-design (case-control) studies is certainly the most commonly known design prone to overestimate index test accuracy. 65 Using healthy controls traditionally leads to spectrum bias, due to enrollment of patients with high suspicion of the disease arising from serial testing or the presence of several positive clinical signs or paraclinical tests (ie, representing more severely affected animals so being worse in terms of the spectrum of BRD signs) compared to control animals which are healthy (ie, absence of all the clinical signs and negative to the paraclinical tests). In the studies we included, the risk of bias was assessed as "high" based on how BRDpos cases were defined, versus those classified as BRDneg healthy controls. Commonly, a 2-gate approach was used, where cases were based on different selection criteria than those used to define healthy controls. For instance, in several studies, BRDpos was based on the presence of a fever, whereas BRDneg cases were those animals not pulled for any assessment (including any determination of rectal temperature to say they do not have a fever) when pen riders visually assessed the animals each day. This approach is recognized as having high potential to overestimate the sensitivity of a test 66 because only the more severely affected animals would undergo the reference standard of rectal temperature measurement for inclusion as BRDpos cases.
Details such as randomized or consecutive sampling in the population were often not included to allow determination of whether the patient selection was unbiased. The fact that the majority of studies did not provide an inclusion flow diagram of the patients, detailing how many were eligible and alternatively excluded, also suggested potential bias. These types of study characteristics have been shown to increase the diagnostic odds ratio of a test (which is an index of global test accuracy; increasing when either Se or Sp increases) in human medical literature. 65 Using flow diagrams such as reported in a recent study 49 can be a quick and effective way to help to understand the sampling strategy as well as any case not retained in the article.
Another concern arising from assessing the risk of bias of the studies was that frequently it was not possible to ensure that interpretation of either the reference standard (BRD diagnosis) or the index test application (cases selected to undergo APP measurement) occurred independent of each other. For example, often it was unclear whether the researcher selected cases for APP testing based on a previous suspicion of BRD (observation of clinical signs) by the producer. Similarly, in some studies, it was not clear whether the test cutoff used to assign animals to BRDpos or BRDneg groups in a binary fashion was determined in advance of the study, versus being selected after data collection, which would have a clear impact on the assessment of diagnostic accuracy in such studies.
67
As an overall observation regarding results from the QUADAS2 evaluation of our included studies, the majority of studies were assessed as having either high or unclear risk of bias, or applicability concerns were rated as high or unclear. It was very interesting to note that most of time we could not differentiate a high versus a low risk of bias within a study due to the absence of a clear mention of the methodology used by the authors; therefore, by default, an "unclear" risk or concern category was chosen in the QUADAS2 tool. This is also a common pitfall of many diagnostic studies in human medicine. 68 However, this could very readily be avoided through more explicit reporting of methodology by authors, allowing stronger conclusions to be drawn from their studies. We voluntarily included studies where the diagnostic accuracy was not the primary objective of the study. This might have been another reason why the reporting could have been heterogeneous when compared with studies in which assessment of diagnostic accuracy of an index test was the primary objective.
In conclusion, we have found that the data concerning the diagnostic accuracy of APP for BRD diagnosis are scant and partially reported. Prior studies have provided the sensitivity and specificity of various acute-phase proteins in the diagnosis of BRD under field conditions, with variable results being seen in terms of the individual APP studied, the test cutoff used to define disease, whether the APP were used alone or in parallel, and timing of test application to case diagnosis. Through our systematic review process, we attempted to take this knowledge surrounding the use of APP to a deeper level of understanding in terms of diagnosing BRD, but could not as a result of such differing study designs and reporting. Since definition of BRDpos and BRDneg cases varied from study to study, it was difficult to explain if observed variation in APP test accuracy was due to study characteristics, sampling, the test cutoff used, or difference in the reference standard. We could, therefore, not conclude on the added value of using APP tests to rule-in or rule-out BRD. In light of the challenges experienced during this systematic review of the literature, we recommend that effort be invested into first establishing a more standardized case definition of BRD in cattle, as well as enforcing a more structured approach to reporting studies on diagnostic test accuracy, using for example, the STAndard for Reporting Diagnostic accuracy studies (STARD) statement. 69 Systematic reviews and meta-analyses provide an opportunity for drawing more meaningful interpretations from the collective data of multiple studies. Challenges encountered in this study, as in other systematic reviews, highlight the need for improved and standardized study reporting such that the scientific community is able to maximize the value and usefulness of future research data. 
